[fusion_builder_container hundred_percent= »no » equal_height_columns= »no » hide_on_mobile= »small-visibility,medium-visibility,large-visibility » background_position= »center center » background_repeat= »no-repeat » fade= »no » background_parallax= »none » parallax_speed= »0.3″ video_aspect_ratio= »16:9″ video_loop= »yes » video_mute= »yes » overlay_opacity= »0.5″ border_style= »solid »][fusion_builder_row][fusion_builder_column type= »1_1″ layout= »1_1″ background_position= »left top » background_color= » » border_size= » » border_color= » » border_style= »solid » border_position= »all » spacing= »yes » background_image= » » background_repeat= »no-repeat » padding= » » margin_top= »0px » margin_bottom= »0px » class= » » id= » » animation_type= » » animation_speed= »0.3″ animation_direction= »left » hide_on_mobile= »small-visibility,medium-visibility,large-visibility » center_content= »no » last= »no » min_height= » » hover_type= »none » link= » »][fusion_text]
Summary
Topic: H2020 SC1-DTH-06-2020Accelerating the uptake of computer simulations for testing medicines and medical devices
Type of action: RIA Research and Innovation action
Deadline Model : single-stage
Deadline: 18 June 2020 17:00:00 Brussels time
Deadline for EoIs: 30th April 2020
Summary: A consortium is preparing a proposal for the call SC1-DTH-06-2020 in the thematic area of cardiovascular disease with new deadline 18/06/2020 . They are looking for a company from EU with expertise in standardisation and regulatory framework of preclinical trials for in silico trials of nanocarriers (NCs) from Germany, France, Italy or Spain
Description
A consortium is preparing a proposal for the topic SC1-DTH-06-2020 “Accelerating the uptake of computer simulations for testing medicines and medical devices” with deadline 18/06/2020. The Proposal will develop innovative scientific and technological computer modelling solutions for testing medicines and/or medical devices in the thematic area of cardiovascular disease. The proposed computer modelling solutions will be the result of a multidisciplinary effort (e.g. within the fields of computational modelling, chemo/bio-informatics, systems biology, pharmacology, -omics (genomics, epigenomics, metabolomics), tissue mechanics, biology, pharmaceutics, medicine, physiology, toxicology, social science aspects such as gender) and should also explore and inform of the reasons for failure should the drug or medical device be found not efficient or safe and will suggest improvements.
They are looking for a company from Germany, France, Italy or Spain with expertise in standardisation and regulatory framework of preclinical trials for in silico trials of nanocarriers (NCs)[/fusion_text][fusion_imageframe image_id= »80989″ style_type= »none » hover_type= »none » align= »center » lightbox= »no » alt= »Enterprise Europe Network » linktarget= »_self » hide_on_mobile= »small-visibility,medium-visibility,large-visibility » animation_direction= »left » animation_speed= »0.3″]https://www.afssi.fr/wp-content/uploads/2020/04/logo-een-300×169.jpg[/fusion_imageframe][fusion_separator style_type= »single solid » hide_on_mobile= »small-visibility,medium-visibility,large-visibility » top_margin= »20px » bottom_margin= »50px » icon= »fa-search » alignment= »center » /][fusion_text]
Votre contact
Cristina Pascual – cpascual@ekt.gr avant le 30/04/2020[/fusion_text][/fusion_builder_column][/fusion_builder_row][/fusion_builder_container]
